<p>Krystal Biotech, Inc.（纳斯达克代码：KRYS - 获取免费报告）周一创下了 52 周的新高。该股最高交易价格为 314.00 美元，最后交易价格为 310.6340 美元，成交量为 23480 股。该股此前收盘价为 305.71 美元。</p>
<p>获取 <strong>Krystal Biotech</strong> 的提醒：</p>
<h2>分析师升级与降级</h2>
<ul>
<li>制药行业抛售：3 只 RSI 显示你不应忽视的股票</li>
</ul>
<p>KRYS 已成为多份研究分析师报告的主题。Weiss Ratings 在 4 月 9 日的研究报告中将 Krystal Biotech 的评级从 “持有（c+）” 上调至 “买入（b-）”。美国银行在 1 月 22 日的报告中将 Krystal Biotech 的目标价从 288.00 美元上调至 318.00 美元，并给予该公司 “买入” 评级。Zacks Research 在 2 月 5 日的报告中将 Krystal Biotech 的评级从 “强力买入” 下调至 “持有”。Jefferies Financial Group 在 2 月 17 日的报告中将 Krystal Biotech 的目标价从 310.00 美元上调至 371.00 美元，并给予该公司 “买入” 评级。最后，HC Wainwright 在 5 月 4 日的报告中重新发布了 “买入” 评级，并设定了 310.00 美元的目标价。十位投资分析师对该股给予了 “买入” 评级，两位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “适度买入”，平均目标价为 324.11 美元。</p>
<p><strong>获取我们对 Krystal Biotech 的最新股票分析</strong></p>
<h2>Krystal Biotech 股票上涨 2.1%</h2>
<ul>
<li>清晰透明：Krystal Biotech 在良好成交量中突破阻力位</li>
</ul>
<p>该公司的 50 日移动平均线为 263.06 美元，200 日移动平均线为 248.61 美元。公司市值为 92 亿美元，市盈率为 41.76，贝塔值为 0.50。</p>
<p>Krystal Biotech（纳斯达克代码：KRYS - 获取免费报告）于 5 月 4 日发布了季度财报。公司报告季度每股收益为 1.83 美元，超出市场共识预期的 1.45 美元，超出幅度为 0.38 美元。Krystal Biotech 的股本回报率为 19.25%，净利润率为 53.92%。该季度的营业收入为 1.1636 亿美元，而分析师预期为 1.1211 亿美元。平均而言，股票研究分析师预计 Krystal Biotech, Inc.在本年度将发布 7.98 美元的每股收益。</p>
<h2>Krystal Biotech 的内部交易</h2>
<p>在其他新闻中，首席会计官 Kathryn Romano 于 3 月 2 日以 750 股的价格出售了该公司的股票。该股票的平均售价为 267.60 美元，总交易额为 200,700.00 美元。交易完成后，首席会计官直接持有该公司 22,366 股股票，价值为 5,985,141.60 美元。此交易代表其持股比例减少了 3.24%。该交易已在 SEC 的备案中披露，相关信息可在 SEC 网站上查阅。此外，董事 Daniel Janney 于 2 月 24 日以 37,895 股的价格出售了 Krystal Biotech 的股票。该股票的平均售价为 266.88 美元，总价值为 10,113,417.60 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士已出售 116,664 股公司股票，价值为 31,136,828 美元。公司内部人士持有公司股票的 13.10%。</p>
<h2>Krystal Biotech 的机构交易</h2>
<p>一些机构投资者最近买入和卖出了 KRYS 的股票。加拿大皇家银行在第一季度将其在 Krystal Biotech 的持股增加了 145.2%。加拿大皇家银行目前拥有该公司 1,628 股股票，价值 294,000 美元，此前在上一季度又购买了 964 股。AQR Capital Management LLC 在第一季度将其在 Krystal Biotech 的持股增加了 29.9%。AQR Capital Management LLC 目前拥有该公司 12,131 股股票，价值 2,187,000 美元，此前在上一季度又购买了 2,792 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Krystal Biotech 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前拥有该公司 15,893 股股票，价值 2,870,000 美元，此前在上一季度又购买了 688 股。Empowered Funds LLC 在第一季度购买了 Krystal Biotech 的新头寸，价值约为 218,000 美元。最后，Cetera Investment Advisers 在第二季度将其在 Krystal Biotech 的持股增加了 107.9%。Cetera Investment Advisers 目前拥有该公司 4,344 股股票，价值 597,000 美元，此前在上一季度又购买了 2,255 股。86.29% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Krystal Biotech</h2>
<p>（获取免费报告）</p>
<p>Krystal Biotech, Inc 是一家临床阶段的生物技术公司，专注于开发针对罕见皮肤病的基因疗法。公司总部位于宾夕法尼亚州匹兹堡，应用专有的病毒载体递送技术，使修正基因能够直接通过皮肤进行局部给药。通过针对遗传性皮肤病的根本遗传原因，Krystal Biotech 旨在解决高未满足医疗需求的领域，提供潜在的变革性治疗。</p>
<p>该公司的主要产品候选药物 KB103 旨在向患有营养不良性表皮松解症（DEB）患者传递功能性 COL7A1 基因，这是一种严重且常常导致残疾的水疱性疾病。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票超过 Krystal Biotech</li>
<li>疯狂的星期一：这家 SaaS 领导者的反弹只是个开始</li>
<li>5 只有望从 AI 推理热潮中受益的股票</li>
<li>Meta Platforms 在财报后的剧烈波动：分析师的目标价现状</li>
<li>3 只在商品超级周期中受益的金属和矿业股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Krystal Biotech 吗？</h2>
<p>在考虑 Krystal Biotech 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前立即购买……而 Krystal Biotech 并不在名单上。</p>
<p>虽然 Krystal Biotech 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KRYS

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

<p>Krystal Biotech（纳斯达克代码：KRYS）达到了新的 52 周高点 314.00 美元，收盘价为 310.63 美元，交易量为 23,480 股。分析师们对该股票进行了升级，Weiss Ratings 将其评级从 “持有” 上调至 “买入”，而美国银行则将其目标价从 288 美元上调至 318 美元。该公司报告的季度每股收益为 1.83 美元，超出预期，市值为 92 亿美元。内部交易活动包括高管的重大出售，而机构持股比例为 86.29%</p>

<p>Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $314.00 and last traded at $310.6340, with a volume of 23480 shares traded. The stock had previously closed at $305.71.</p>
<div class="lb-trans"><p>Krystal Biotech, Inc.（纳斯达克代码：KRYS - 获取免费报告）周一创下了 52 周的新高。该股最高交易价格为 314.00 美元，最后交易价格为 310.6340 美元，成交量为 23480 股。该股此前收盘价为 305.71 美元。</p>
</div><p>Get <strong>Krystal Biotech</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Krystal Biotech</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级与降级</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药行业抛售：3 只 RSI 显示你不应忽视的股票</li>
</ul>
</div><p>KRYS has been the topic of several research analyst reports. Weiss Ratings upgraded Krystal Biotech from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research note on Thursday, April 9th. Bank of America boosted their price objective on Krystal Biotech from $288.00 to $318.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, January 22nd. Zacks Research cut Krystal Biotech from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, February 5th. Jefferies Financial Group increased their target price on Krystal Biotech from $310.00 to $371.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, February 17th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and set a $310.00 target price on shares of Krystal Biotech in a report on Monday, May 4th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $324.11.</p>
<div class="lb-trans"><p>KRYS 已成为多份研究分析师报告的主题。Weiss Ratings 在 4 月 9 日的研究报告中将 Krystal Biotech 的评级从 “持有（c+）” 上调至 “买入（b-）”。美国银行在 1 月 22 日的报告中将 Krystal Biotech 的目标价从 288.00 美元上调至 318.00 美元，并给予该公司 “买入” 评级。Zacks Research 在 2 月 5 日的报告中将 Krystal Biotech 的评级从 “强力买入” 下调至 “持有”。Jefferies Financial Group 在 2 月 17 日的报告中将 Krystal Biotech 的目标价从 310.00 美元上调至 371.00 美元，并给予该公司 “买入” 评级。最后，HC Wainwright 在 5 月 4 日的报告中重新发布了 “买入” 评级，并设定了 310.00 美元的目标价。十位投资分析师对该股给予了 “买入” 评级，两位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “适度买入”，平均目标价为 324.11 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Krystal Biotech</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Krystal Biotech 的最新股票分析</strong></p>
</div><h2>Krystal Biotech Stock Up 2.1%</h2>
<div class="lb-trans"><h2>Krystal Biotech 股票上涨 2.1%</h2>
</div><ul>
<li>Krystal Clear: Krystal Biotech Clears Resistance in Good Volume</li>
</ul>
<div class="lb-trans"><ul>
<li>清晰透明：Krystal Biotech 在良好成交量中突破阻力位</li>
</ul>
</div><p>The firm has a 50-day moving average of $263.06 and a two-hundred day moving average of $248.61. The company has a market capitalization of $9.20 billion, a PE ratio of 41.76 and a beta of 0.50.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 263.06 美元，200 日移动平均线为 248.61 美元。公司市值为 92 亿美元，市盈率为 41.76，贝塔值为 0.50。</p>
</div><p>Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The business had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. On average, equities research analysts expect that Krystal Biotech, Inc. will post 7.98 EPS for the current year.</p>
<div class="lb-trans"><p>Krystal Biotech（纳斯达克代码：KRYS - 获取免费报告）于 5 月 4 日发布了季度财报。公司报告季度每股收益为 1.83 美元，超出市场共识预期的 1.45 美元，超出幅度为 0.38 美元。Krystal Biotech 的股本回报率为 19.25%，净利润率为 53.92%。该季度的营业收入为 1.1636 亿美元，而分析师预期为 1.1211 亿美元。平均而言，股票研究分析师预计 Krystal Biotech, Inc.在本年度将发布 7.98 美元的每股收益。</p>
</div><h2>Insider Transactions at Krystal Biotech</h2>
<div class="lb-trans"><h2>Krystal Biotech 的内部交易</h2>
</div><p>In other news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the transaction, the chief accounting officer directly owned 22,366 shares in the company, valued at $5,985,141.60. This trade represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel Janney sold 37,895 shares of Krystal Biotech stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $266.88, for a total value of $10,113,417.60. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 116,664 shares of company stock valued at $31,136,828. Corporate insiders own 13.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席会计官 Kathryn Romano 于 3 月 2 日以 750 股的价格出售了该公司的股票。该股票的平均售价为 267.60 美元，总交易额为 200,700.00 美元。交易完成后，首席会计官直接持有该公司 22,366 股股票，价值为 5,985,141.60 美元。此交易代表其持股比例减少了 3.24%。该交易已在 SEC 的备案中披露，相关信息可在 SEC 网站上查阅。此外，董事 Daniel Janney 于 2 月 24 日以 37,895 股的价格出售了 Krystal Biotech 的股票。该股票的平均售价为 266.88 美元，总价值为 10,113,417.60 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士已出售 116,664 股公司股票，价值为 31,136,828 美元。公司内部人士持有公司股票的 13.10%。</p>
</div><h2>Institutional Trading of Krystal Biotech</h2>
<div class="lb-trans"><h2>Krystal Biotech 的机构交易</h2>
</div><p>A number of institutional investors have recently bought and sold shares of KRYS. Royal Bank of Canada lifted its holdings in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company's stock worth $294,000 after buying an additional 964 shares during the last quarter. AQR Capital Management LLC grew its position in Krystal Biotech by 29.9% in the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company's stock valued at $2,187,000 after buying an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company's stock worth $2,870,000 after buying an additional 688 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of Krystal Biotech during the 1st quarter worth approximately $218,000. Finally, Cetera Investment Advisers raised its stake in shares of Krystal Biotech by 107.9% during the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company's stock worth $597,000 after buying an additional 2,255 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近买入和卖出了 KRYS 的股票。加拿大皇家银行在第一季度将其在 Krystal Biotech 的持股增加了 145.2%。加拿大皇家银行目前拥有该公司 1,628 股股票，价值 294,000 美元，此前在上一季度又购买了 964 股。AQR Capital Management LLC 在第一季度将其在 Krystal Biotech 的持股增加了 29.9%。AQR Capital Management LLC 目前拥有该公司 12,131 股股票，价值 2,187,000 美元，此前在上一季度又购买了 2,792 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Krystal Biotech 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前拥有该公司 15,893 股股票，价值 2,870,000 美元，此前在上一季度又购买了 688 股。Empowered Funds LLC 在第一季度购买了 Krystal Biotech 的新头寸，价值约为 218,000 美元。最后，Cetera Investment Advisers 在第二季度将其在 Krystal Biotech 的持股增加了 107.9%。Cetera Investment Advisers 目前拥有该公司 4,344 股股票，价值 597,000 美元，此前在上一季度又购买了 2,255 股。86.29% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Krystal Biotech</h2>
<div class="lb-trans"><h2>关于 Krystal Biotech</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.</p>
<div class="lb-trans"><p>Krystal Biotech, Inc 是一家临床阶段的生物技术公司，专注于开发针对罕见皮肤病的基因疗法。公司总部位于宾夕法尼亚州匹兹堡，应用专有的病毒载体递送技术，使修正基因能够直接通过皮肤进行局部给药。通过针对遗传性皮肤病的根本遗传原因，Krystal Biotech 旨在解决高未满足医疗需求的领域，提供潜在的变革性治疗。</p>
</div><p>The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 KB103 旨在向患有营养不良性表皮松解症（DEB）患者传递功能性 COL7A1 基因，这是一种严重且常常导致残疾的水疱性疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Krystal Biotech</li>
<li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li>
<li>5 Stocks Positioned to Benefit From the AI Inference Boom</li>
<li>Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now</li>
<li>3 Metals and Mining Stocks Riding the Commodity Supercycle</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Krystal Biotech</li>
<li>疯狂的星期一：这家 SaaS 领导者的反弹只是个开始</li>
<li>5 只有望从 AI 推理热潮中受益的股票</li>
<li>Meta Platforms 在财报后的剧烈波动：分析师的目标价现状</li>
<li>3 只在商品超级周期中受益的金属和矿业股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Krystal Biotech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Krystal Biotech 吗？</h2>
</div><p>Before you consider Krystal Biotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Krystal Biotech 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前立即购买……而 Krystal Biotech 并不在名单上。</p>
</div><p>While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Krystal Biotech 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week High  - Here's Why

Market Beat

Krystal Biotech

Invesco Nasdaq Biotechnology ETF

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

医药突破 ETF - ALPS

美国银行

Jefferies Financial

加拿大皇家银行

蒙特利尔银行

加拿大帝国商业银行

Annaly资本管理

Sculptor Capital

Arqit Quantum

Nano Labs

Mirrabooka Investments Ltd

电能实业(ADR)

Costa Group Holdings Ltd. TEMP

女性赋权 ETF - Impact Shares

Nomura Holdings, Inc.

LG QRAFT AI-Powered US Large Cap Core ETF

Japan Investment Adviser Co., Ltd.

Cetus Capital Acquisition Corp.

Russell Investment Management LLC

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

Arqit Quantum - CW26

电能实业

Krystal Biotech（纳斯达克股票代码：KRYS）创下 52 周新高 - 以下是原因